Agilon Health operates a value-based-care enablement platform that helps independent community PCPs move from fee-for-service to full-risk care for Medicare seniors, combining payer contracting, actuarial tools, clinical workflows, and administrative support while leaving practices independent. Its principal revenue is PMPM capitation from Medicare Advantage and CMS risk arrangements; Medical Margin is revenue less medical-service expense, with ACO REACH shared savings as a secondary stream. The turnaround showed measurable progress in Q2 2026: revenue rose 7.2% year over year to $1.495 billion, GAAP net income was $18.0 million versus a $104.4 million loss, Medical Margin was $197 million versus negative $53 million, and adjusted EBITDA was $70 million versus negative $83 million. Results included approximately $22 million of favorable prior-period claims development. Management raised FY2026 revenue guidance to $5.775–$5.860 billion, Medical Margin to $465–$505 million, and adjusted EBITDA to $75–$95 million. **The key catalyst is the contract reset, which generated over $120 million of FY2026 value.** At $80.73 in late September 2026, shares traded at about 0.2x forward sales but 52.9x consensus FY2027 non-GAAP EPS of $1.82. **The investment remains a high-risk margin-stability turnaround**, with the report’s probability-weighted five-year value at $156.30 and substantial downside if claims costs reaccelerate.

agilon health inc (AGL) Investment Analysis

1. Executive Summary

agilon health, inc. (NYSE: AGL) operates as a value-based healthcare enablement platform designed to empower independent, community-based primary care physicians (PCPs) across the United States [cite: 1, 2, 3]. The company’s core operational framework assists primary care providers in transitioning away from traditional fee-for-service reimbursement models toward full-risk, total-cost-of-care capitation arrangements [cite: 1, 3]. Through long-term joint operating agreements, agilon equips independent physician practices with the operational infrastructure, clinical workflow technology, actuarial risk models, and administrative resources necessary to manage health outcomes and total medical expenditures for senior patients [cite: 2, 3].

                     +---------------------------------------+
                     |         AGILON HEALTH PLATFORM        |
                     +---------------------------------------+
                                         |
            +----------------------------+----------------------------+
            |                                                         |
            v                                                         v
+-----------------------+                                 +-----------------------+
|  MEDICARE ADVANTAGE   |                                 |       ACO REACH       |
|   Capitated PMPM      |                                 |    Shared Savings /   |
|   Revenue Stream      |                                 |     Risk Model        |
+-----------------------+                                 +-----------------------+
            |                                                         |
            +----------------------------+----------------------------+
                                         |
                                         v
                     +---------------------------------------+
                     |       TOTAL CARE MODEL PLATFORM       |
                     |  Actuarial, Workflows, Data Analytics |
                     +---------------------------------------+
                                         |
                                         v
                     +---------------------------------------+
                     |     INDEPENDENT PCP PARTNERSHIPS      |
                     |   Shared Surplus & Medical Margin     |
                     +---------------------------------------+

The economic engine of the company relies primarily on monthly per-member-per-month (PMPM) capitation payments received from Medicare Advantage (MA) health plans and the Centers for Medicare & Medicaid Services (CMS) under global risk agreements [cite: 2, 3, 4]. Under these contracts, agilon assumes full financial responsibility for the comprehensive healthcare costs of covered beneficiaries [cite: 3]. The primary revenue metric generated by this mechanism is the "Medical Margin," which represents total capitation revenue minus total medical services expenses [cite: 3, 5, 6]. A secondary revenue stream is derived from participation in federal Accountable Care Organization (ACO) initiatives, specifically the CMS ACO REACH model, which rewards shared savings and risk management for Original Medicare beneficiaries [cite: 5, 7].

Operational Metric	Strategic Details and Figures
Core Offering	Total Care Model (Full-risk value-based care enablement platform) [cite: 1, 3]
Primary Customer Types	Independent Primary Care Physician (PCP) practices and regional medical groups [cite: 1, 3]
Target End Market	U.S. senior population enrolled in Medicare Advantage and Original Medicare [cite: 2, 3, 5]
Revenue Model	Capitated PMPM subscription-style payments from payors and CMS [cite: 2, 3, 4]
Geographic Footprint	Distributed across multiple regional U.S. metropolitan and community healthcare markets [cite: 3]

The core end market for agilon is the rapidly expanding U.S. senior demographic [cite: 2, 3, 8]. Independent primary care practices select agilon over alternative structural arrangements—such as hospital health system acquisitions or direct sales to payer-owned health networks—because agilon’s model preserves physician operational autonomy while granting access to enterprise-grade technology and risk-bearing capabilities [cite: 1, 3, 4]. By establishing capital-light co-management entities, agilon enables community physicians to capture the upside of value-based care without selling their clinical practices or sacrificing clinical independence [cite: 3, 4].

2. Business Drivers & Strategic Overview

Evaluating agilon health’s economic performance requires examining its product architecture, competitive moat, addressable market scale, and positioning within the broader healthcare ecosystem.

Product and Service Detail

agilon sells a standardized, enterprise-wide operating system for value-based senior care branded as the "Total Care Model" [cite: 1, 3]. This platform incorporates several critical components:

• Payer Contracting and Risk Aggregation: agilon aggregates local physician networks to negotiate full-risk capitation contracts with national Medicare Advantage health insurance carriers [cite: 3].
• Actuarial and Medical Margin Analytics: The platform deploys internal actuarial models to forecast medical utilization, track disease burden accruals, and manage Incurred But Not Reported (IBNR) claims reserves [cite: 1].
• EHR-Embedded Clinical Workflows: Software integrations provide PCPs with point-of-care alerts to address care gaps, manage complex chronic illnesses, execute annual wellness visits, and direct specialist referrals toward high-efficiency networks [cite: 3, 6].
• Risk Restructuring and Specialty Management: In response to industry-wide medical cost trends, agilon has restructured payor contracts to carve out volatile liabilities, such as high-cost Part D specialty pharmaceuticals, while implementing tighter utilization protocols for inpatient and specialist care [cite: 3, 9].

Moat Analysis

agilon’s competitive position relies on a combination of structural switching costs, local network scale, and contract aggregation leverage:

• High Switching Costs: agilon enters into long-duration joint operating agreements (historically up to 20 years) with anchor primary care practices [cite: 3, 4]. Once a medical group integrates its clinical routines, data infrastructure, and payor reimbursement contracts into agilon’s architecture, untangling those operations imposes substantial administrative friction and financial risk [cite: 3].
• Payor Contracting Leverage and Scale: By consolidating regional panels of independent physicians into unified risk entities, agilon commands superior PMPM rates and favorable risk-share terms from major health plans that individual medical practices cannot negotiate independently [cite: 3].
• Local Network Density: Concentrating partner practices within defined geographic regions creates cost advantages when negotiating preferred rates with local hospital systems, outpatient surgical centers, and specialist networks [cite: 3].

Market Opportunity (TAM)

The addressable market for value-based senior care enablement is driven by demographic tailwinds [cite: 8]. agilon estimates its immediate addressable opportunity across core markets at approximately 10.5 million Medicare Advantage beneficiaries and more than 33,000 primary care physicians, representing several hundred billion dollars in total annual medical expenditures [cite: 6]. With approximately 10,000 Americans turning 65 every day, the total pool of eligible Medicare lives continues to expand [cite: 8].

Competitive Landscape

agilon operates in a multi-segmented sector consisting of pure-play risk enablement platforms, payer-owned care networks, and clinic-centric care delivery models.

Competitor Category	Primary Competitors	Positioning relative to agilon health	Market Share Momentum
Direct Enablement Peers	Astrana Health (ASTH), Privia Health (PRVA) [cite: 10]	Astrana and Privia emphasize lighter risk-sharing or fee-for-service hybrid models, whereas agilon focuses predominantly on full-risk MA capitation [cite: 3, 10].	Holding ground in full-risk; Privia winning lighter-risk practices [cite: 3, 10].
Payer-Owned Delivery Networks	Optum Care (UnitedHealth), CenterWell (Humana) [cite: 3, 10]	Vertically integrated or fully acquired physician groups backed by national payer balance sheets [cite: 3, 10].	Gaining ground through direct practice acquisitions [cite: 3, 10].
Clinic-Centric VBC Models	Oak Street Health (CVS), ChenMed [cite: 10]	Dedicated de novo senior centers requiring significant capital expenditure per location [cite: 3, 10].	Growing deliberately due to high capital requirements [cite: 3, 10].

agilon’s strategic pivot since late 2025 has prioritized margin preservation and operational discipline over unconstrained membership growth [cite: 5, 7, 11]. By severing non-performing physician contracts, exiting unprofitable markets, and capping Part D drug liabilities, agilon is streamlining its operating footprint to build a more resilient core enterprise [cite: 5, 7, 9].

3. Financial Performance & Valuation

Most Recent Quarterly Performance (Q2 2026)

agilon health reported its Q2 2026 financial results on August 4, 2026, for the quarterly period ended June 30, 2026 [cite: 7, 12, 13]. The performance demonstrated a turnaround in core operating metrics following severe utilization headwinds faced in fiscal 2025 [cite: 7, 14].

It is critical to note that on March 30, 2026, agilon executed a 1-for-25 reverse stock split to maintain compliance with NYSE listing requirements [cite: 15, 16, 17]. All per-share data for 2026 reflect this split-adjusted capital structure [cite: 15, 18, 19].

• Total Revenue: Q2 2026 revenue rose to $1.495 billion, representing a 7.2% year-over-year increase compared to $1.395 billion in Q2 2025 [cite: 7, 20]. Revenue beat consensus analyst expectations of $1.448 billion by approximately 3.2% [cite: 20, 21].
• Earnings Per Share (EPS): Reported diluted EPS for Q2 2026 reached $1.04 per share (post-split) [cite: 12, 18]. This beat consensus analyst estimates of $0.14 per share by $0.90 [cite: 12]. This represents a sharp improvement from a net loss per share of $(6.31) (split-adjusted) in Q2 2025 [cite: 18, 20].
• Net Income and Gross Profit: GAAP net income reached $18.0 million, compared to a GAAP net loss of $(104.4) million in Q2 2025 [cite: 7, 20]. Gross profit reached $107 million, recovering from a gross loss of $(52) million in the prior-year quarter [cite: 7].
• Medical Margin and Adjusted EBITDA: Q2 2026 Medical Margin expanded to $197 million, compared to negative $(53) million in Q2 2025 [cite: 7]. Adjusted EBITDA reached $70 million, up from negative $(83) million in Q2 2025 [cite: 7]. Favorable prior-period claims development provided an approximate $22 million tailwind to these results [cite: 9].
• Membership Scale: Total platform membership stood at 549,000 (comprising 437,000 Medicare Advantage members and 112,000 ACO REACH beneficiaries) [cite: 7]. Total membership declined 10% year-over-year as agilon intentionally exited unprofitable geographic markets and low-margin provider arrangements [cite: 5, 7].

Metric (in $ Millions, except per share)	Q2 2026 Actual	Q2 2025 Actual	YoY Change	Consensus Est.	Performance vs. Consensus
Total Revenue	$1,495	$1,395	+7.2%	$1,448	Beat (+3.2%) [cite: 7, 20, 21]
GAAP Net Income (Loss)	$18.0	$(104.4)	Inflected	$(12.0)	Beat [cite: 7, 12, 20]
Diluted EPS (Post-Split)	$1.04	$(6.31)	Inflected	$0.14	Beat (+$0.90) [cite: 12, 18, 20]
Medical Margin	$197.0	$(53.0)	Inflected	N/A	Exceeded internal targets [cite: 7]
Adjusted EBITDA	$70.0	$(83.0)	Inflected	N/A	Exceeded internal targets [cite: 7]
Medicare Advantage Members	437,000	498,000	-12.2%	430,000	Exceeded midpoint guidance [cite: 7]

Management Guidance & Strategic Commentary

Following Q2 2026 performance, management raised full-year 2026 operational guidance across all core financial metrics [cite: 7]:

• Full-Year Revenue Guidance: Increased to $5.775 billion–$5.860 billion (up from $5.680 billion–$5.805 billion) [cite: 7, 21].
• Full-Year Medical Margin Guidance: Raised to $465 million–$505 million (up from $350 million–$400 million) [cite: 7].
• Full-Year Adjusted EBITDA Guidance: Elevated to $75 million–$95 million (up from $10 million–$40 million) [cite: 7].

Management highlighted contract re-negotiations as the core catalyst for operational stabilization [cite: 9]. The company modified terms across 80% of its payor contracts during 2025, realizing over $120 million in value for fiscal 2026 [cite: 9]. Furthermore, agilon reduced its Part D specialty drug exposure from 30% of platform membership in 2025 to under 15% in 2026 [cite: 5, 9]. Full-year baseline medical cost trends remain assumed in the low 7% range [cite: 7, 9].

Analyst Sentiment & Stock Reaction

The market reaction following the earnings release and subsequent operational updates reflected ongoing sentiment shifts [cite: 21, 22]. Following the post-split bottom in early 2026, the stock mounted a recovery driven by positive EBITDA revisions and major broker upgrades [cite: 8, 21]. Bernstein upgraded AGL to Outperform with a $125 price target in September 2026, citing cost discipline [cite: 21]. However, on September 24, 2026, Citi downgraded the stock from Neutral to Sell, noting that the rapid price recovery left shares trading at a premium valuation ahead of prospective 2027 Medicare Advantage rate adjustments [cite: 8, 22]. As of late September 2026, AGL closed at $80.73 per share, yielding a market capitalization of ~$1.37 billion [cite: 8, 13, 18].

Core Financial Drivers & Valuation Metrics

To evaluate agilon’s valuation structure, investors must track its key balance sheet and historical metrics:

• Revenue Growth Trajectory: Historical 5-year revenue CAGR stands at +24.5%, though near-term top-line expansion has slowed due to intentional platform consolidation [cite: 7, 18].
• Balance Sheet and Cash Position: As of June 30, 2026, agilon held $257 million in consolidated cash, cash equivalents, and marketable securities, with an additional $83 million held in unconsolidated ACO entities [cite: 7, 9]. Total debt remains modest at $30.3 million to $32.0 million [cite: 7, 17]. Management expects ending FY2026 with at least $125 million in consolidated cash reserves [cite: 9].
• Valuation Multiples: At $80.73 per share, agilon trades at a Forward P/S multiple of ~0.2x on FY2026 consensus revenue [cite: 8]. Forward P/E based on consensus FY2027 projected non-GAAP net income ($1.82 EPS) stands at ~52.9x [cite: 8].

4. Risk Assessment & Macroeconomic Considerations

Understanding agilon health’s risk profile requires analyzing the operational, regulatory, and macroeconomic headwinds that impacted the business during 2024–2025.

Company-Specific Execution Risks

• Incurred But Not Reported (IBNR) Claims Volatility: Capitation economics depend heavily on actuarial accruals for medical services rendered but not yet billed [cite: 1, 8]. Historically, agilon experienced negative prior-period development when lag-time claims for specialist care and outpatient procedures exceeded internal estimates [cite: 5, 8, 23].
• Physician Compliance and Care Management: Because agilon does not directly employ partner physicians, clinical cost containment relies on voluntary PCP adherence to care management protocols [cite: 3]. Weak PCP engagement erodes Medical Margins [cite: 3, 23].

Competitive & Customer Concentration Risks

• Payor Concentration: A major portion of agilon’s capitated revenue is concentrated among major health plans, including Humana, Aetna, and UnitedHealth Group [cite: 3]. Payor efforts to reduce administrative fees or shift risk terms pose top-line risks [cite: 3, 22].
• Competition from Vertically Integrated Payers: Competitors like Optum Care possess vast balance sheets that allow them to offer aggressive acquisition terms to independent primary care groups [cite: 3, 10].

Regulatory, Legal & Structural Industry Risks

• CMS Risk Adjustment Model Changes (CMS-HCC V28): The implementation of CMS's V28 risk-scoring framework systematically lowers risk coefficients for several chronic condition categories [cite: 7]. While agilon projects a +3% net risk score expansion in 2026, future coding restrictions could constrain PMPM revenue growth [cite: 7].
• Securities Class Action Litigation: Following the 2025 management disruption and guidance suspension, multiple shareholder class action lawsuits were filed alleging misleading disclosures regarding medical cost trends [cite: 8, 22, 24, 25]. These lawsuits create headline volatility and legal defense expenses [cite: 8].

Macroeconomic Sensitivities

• Medical Cost Inflation: Escalating facility fees, specialist billing rates, and clinical labor costs elevate overall healthcare expenditures [cite: 6, 8]. If medical inflation exceeds annual CMS benchmark rate updates, agilon’s operating margins contract [cite: 3, 8].

The core structural threat to agilon’s long-term business model lies in a compound operational failure chain. If outpatient medical utilization re-accelerates unexpectedly, and contractual Part D risk carve-outs fail to fully insulate the company from pharmaceutical inflation, agilon's Medical Loss Ratio (MLR) could exceed capitation benchmarks [cite: 3, 8, 9]. Such an environment would compress Medical Margins, leading to rapid cash burn and threatening long-term solvency [cite: 5, 8, 9].

• What Could Go Wrong: A secondary surge in senior post-acute utilization or specialized therapy demand could outpace restructured payor contract rates, pushing Medical Margins back into negative territory [cite: 5, 8].
• Early Warning Signs: Negative prior-period development reported in quarterly SEC filings, widening discrepancies between paid claims data and actuarial reserves, or anchor physician practice departures [cite: 1, 5, 9].
• Thesis Breakers: Failure to sustain positive net operating income and operating cash flows by FY2027, forcing dilutive equity raises or debt restructuring [cite: 8].

5. 5-Year Scenario Analysis

The 5-year scenario model evaluates agilon health’s fundamental valuation trajectory through FY2031. Models are anchored on the post-split capital structure of 17.0 million diluted shares outstanding and a baseline share price of $80.73 USD as of late September 2026 [cite: 13, 15, 18].

Scenario Assumptions & Fundamentals

Base Case (50% Probability)

• Revenue Growth: 6.5% CAGR from FY2026 baseline ($5.82B), reaching $7.98 billion in FY2031, supported by steady organic membership expansion in established markets [cite: 7, 8].
• Net Profit Margin: Reaches 2.5% by FY2031 as platform scale, Part D risk carve-outs, and contract revisions take full effect [cite: 7, 9].
• FY2031 Net Income: $199.5 million USD.
• Share Count: Expands modestly to 18.0 million shares due to standard executive stock compensation grants [cite: 11, 26].
• FY2031 Diluted EPS: $11.08 USD.
• Exit Valuation Multiple: 12.0x P/E (~0.30x Price/Sales), matching valuations for mature healthcare enablement platforms [cite: 8].
• Implied FY2031 Share Price: $133.00 USD.
• 5-Year Total Return: +64.75% | Annualized Return (CAGR): +10.50%.

High Case (25% Probability)

• Revenue Growth: 10.0% CAGR, reaching $9.37 billion in FY2031, driven by market share expansion and strong ACO REACH growth [cite: 6, 7].
• Net Profit Margin: Expands to 4.0% via effective specialty cost containment and medical loss ratio optimization [cite: 3, 9].
• FY2031 Net Income: $374.8 million USD.
• Share Count: Maintained at 17.5 million shares through share buybacks funded by free cash flow.
• FY2031 Diluted EPS: $21.42 USD.
• Exit Valuation Multiple: 16.0x P/E, reflecting market-leading position and cash flow compounding [cite: 8].
• Implied FY2031 Share Price: $342.68 USD.
• 5-Year Total Return: +324.48% | Annualized Return (CAGR): +33.52%.

Low Case (25% Probability)

• Revenue Growth: 2.0% CAGR, reaching $6.43 billion in FY2031, constrained by CMS rate cuts and partner physician exits [cite: 5, 7].
• Net Profit Margin: Stagnates at 0.5% due to recurring medical utilization spikes and IBNR reserve shortfalls [cite: 8, 23].
• FY2031 Net Income: $32.1 million USD.
• Share Count: Expands to 19.5 million shares due to dilutive capital raises needed to bolster operating cash [cite: 8].
• FY2031 Diluted EPS: $1.65 USD.
• Exit Valuation Multiple: 10.0x P/E, reflecting weak margin stability [cite: 8].
• Implied FY2031 Share Price: $16.50 USD.
• 5-Year Total Return: -79.56% | Annualized Return (CAGR): -27.13%.

5-Year Share Price Trajectory (USD)

Fiscal Year	Low Case ($)	Base Case ($)	High Case ($)
Current (2026)	$80.73	$80.73	$80.73 [cite: 13]
2027 Projected	$55.00	$90.00	$120.00
2028 Projected	$38.00	$102.00	$165.00
2029 Projected	$26.00	$112.00	$220.00
2030 Projected	$20.00	$122.00	$280.00
2031 Projected	$16.50	$133.00	$342.68

Compact Scenario Table

Scenario	Revenue / key scale metric in Year 5	Margin / earnings assumption	Valuation multiple assumption	Current share price	Implied future share price	5-year total return	Annualized return	Probability
Base Case	$7.98 Billion	2.5% Net Margin ($199.5M Net Income)	12.0x P/E (0.30x P/S)	$80.73 USD	$133.00 USD	+64.75%	+10.50%	50.00%
High Case	$9.37 Billion	4.0% Net Margin ($374.8M Net Income)	16.0x P/E (0.40x P/S)	$80.73 USD	$342.68 USD	+324.48%	+33.52%	25.00%
Low Case	$6.43 Billion	0.5% Net Margin ($32.1M Net Income)	10.0x P/E (0.15x P/S)	$80.73 USD	$16.50 USD	-79.56%	-27.13%	25.00%
Weighted	$7.94 Billion	2.38% Net Margin	12.5x P/E	$80.73 USD	$156.30 USD	+93.61%	+14.12%	100.00%

$\text{Probability-Weighted Fair Value Target} = (0.50 \times \$133.00) + (0.25 \times \$342.68) + (0.25 \times \$16.50) = \$156.30 \text{ USD}$

HIGH ASYMMETRIC VOLATILITY

6. Qualitative Scorecard

agilon health demonstrates a complex qualitative profile, balancing operational stabilization against historical execution challenges [cite: 7, 11].

Management Alignment: 6 / 10

The leadership team underwent a restructuring in May 2026, appointing CEO Tim O'Rourke alongside CFO Jeff Schwaneke (formerly of Centene) [cite: 11, 14]. Co-founders Ron Williams and Ravi Sachdev (CD&R) maintain active oversight via the board [cite: 11]. However, sizeable executive retention packages were required to stabilize C-suite turnover following the 2025 leadership departure [cite: 11].

Revenue Quality: 7 / 10

Revenue is generated via recurring capitated PMPM agreements, offering top-line visibility [cite: 2, 4]. However, underlying earnings quality remains tied to medical loss ratios and payor contract terms [cite: 3, 9].

Market Position: 6 / 10

agilon holds a primary care enablement footprint among independent physician groups [cite: 1, 3]. Top-line market share expansion has slowed intentionally as management exits unprofitable regional contracts [cite: 5, 7].

Growth Outlook: 5 / 10

Near-term growth is restrained by market exits and contract renegotiations [cite: 5, 7]. Long-term tailwinds remain anchored in aging demographic shifts [cite: 8].

Financial Health: 6 / 10

Balance sheet health has stabilized, supported by $257 million in cash and modest debt of $30 million [cite: 7, 9, 17]. Q2 2026 demonstrated a return to net profitability, though historical cash flow generation remains irregular [cite: 7, 8, 20].

Business Viability: 6 / 10

The platform provides a value proposition for independent PCPs transitioning to value-based care [cite: 1, 3]. However, long-term viability requires sustained control over medical cost trends relative to CMS benchmarks [cite: 3, 8].

Capital Allocation: 5 / 10

Historical capital allocation was aggressive, expanding into low-margin geographic markets that later required operational exits [cite: 5, 7, 11]. Current management demonstrates greater capital discipline focused on margin improvement [cite: 7, 9].

Analyst Sentiment: 6 / 10

Wall Street sentiment is divided following the stock's 2026 recovery [cite: 21, 22]. Upgrades from Bernstein ($125 price target) are counterbalanced by downgrades from Citi (Sell) over valuation concerns [cite: 8, 21, 22].

Profitability: 5 / 10

Operating performance inflected positively in Q2 2026 ($18.0M Net Income, $70M Adj. EBITDA) [cite: 7]. However, net profit margins remain thin and sensitive to utilization surges [cite: 8].

Track Record: 3 / 10

The historic track record includes severe shareholder value destruction throughout 2024–2025, culminating in a 70%+ stock decline, guidance suspension, and a 1-for-25 reverse stock split [cite: 11, 15].

Blended Qualitative Score: 5.5 / 10

Calculated weighted assessment reflecting operational turnaround progress balanced against execution risks.

TURNAROUND IN PROGRESS

7. Conclusion & Investment Thesis

agilon health presents a value-based care turnaround profile [cite: 11, 21]. The company's core value proposition—enabling independent primary care physicians to succeed under full-risk capitation—addresses structural demands within the U.S. healthcare delivery system [cite: 1, 3].

The fundamental thesis centers on three primary catalysts:
* Contract Restructuring Benefits: Re-negotiating terms across 80% of payor contracts captured over $120 million in value for fiscal 2026, establishing a higher baseline medical margin [cite: 9].
* De-risking High-Cost Liabilities: Reducing Part D specialty drug exposure to under 15% of platform members insulates the company from high-cost pharmaceutical inflation [cite: 9].
* Leadership Focus on Profitability: C-suite leadership under CEO Tim O'Rourke and CFO Jeff Schwaneke prioritizes margin discipline and cash preservation over unconstrained membership expansion [cite: 7, 9, 11].

Conversely, thesis risks remain centered on medical cost volatility, actuarial reserve accuracy (IBNR), and ongoing changes to CMS risk-adjustment scoring models (V28) [cite: 1, 7, 8]. While Q2 2026 results demonstrated that the business can generate positive net income and Adjusted EBITDA under restructured contract terms, maintaining margin stability across fluctuating healthcare utilization cycles will determine long-term value creation [cite: 7, 8, 9].

HIGH-RISK TURNAROUND INFLECTION

8. Technical Analysis, Price Action & Short-Term Outlook

AGL stock trades near $80.73 USD following a multi-hundred percent split-adjusted rally from its early-2026 lows [cite: 8, 13, 21]. The company executed a 1-for-25 reverse stock split in late March 2026 to maintain listing compliance [cite: 15, 17]. Currently, the share price trades above its rising 50-day moving average but faces technical resistance near its post-split 52-week peak of $133.04 [cite: 8, 27]. Recent price action reflects consolidation following Wall Street profit-taking and a downgrade by Citi citing valuation [cite: 8, 22]. The short-term outlook depends on upcoming quarterly claims development and margin metrics [cite: 8, 9].

CONSOLIDATING NEAR RESISTANCE

---

1. Manager, Actuarial Services – Tools & Models at agilon health - Jobgether, https://jobgether.com/offer/6aa9ff83b563ea142eb0be44-manager-actuarial-services---tools-models
2. Agilon Health Inc. (AGL) Stock Price & Live Chart - Saxo Bank, https://www.home.saxo/markets/stocks/agl-xnys
3. Agilon Health Strategy and Business Model - Umbrex Consulting, https://umbrex.com/resources/company-profiles/agilon-health/
4. agilon health Investor Presentation, https://s27.q4cdn.com/807105172/files/doc_presentations/2022/11/agilon-Investor-Deck-December-2022-(1).pdf
5. agilon health Reports First Quarter 2025 Results, https://investors.agilonhealth.com/news/news-details/2025/agilon-health-Reports-First-Quarter-2025-Results/default.aspx
6. Investor Presentation., https://s27.q4cdn.com/807105172/files/doc_presentations/2023/agilon-health-Investor-Presentation-June-2023.pdf
7. agilon health Reports Second Quarter 2026 Results, https://investors.agilonhealth.com/news/news-details/2026/agilon-health-Reports-Second-Quarter-2026-Results/default.aspx
8. Agilon Health (AGL) - Trefis, https://www.trefis.com/data/companies/AGL
9. agilon health at jefferies conference: turnaround gains ground - Investing.com UK, https://uk.investing.com/news/stock-market-news/agilon-health-at-jefferies-conference-turnaround-gains-ground-93CH-4868656
10. Astrana Health Strategy and Business Model - Umbrex, https://umbrex.com/resources/company-profiles/astrana-health/
11. agilon health, inc. (AGL) Management Team Experience & Alignment (2026) - KoalaGains, https://koalagains.com/stocks/NYSE/AGL/management-team
12. Agilon Health (AGL) Earnings: Latest Report, Earnings Call & Financials, https://public.com/stocks/agl/earnings
13. agilon health (AGL) Stock Price, News & Analysis - Stock Titan, https://www.stocktitan.net/overview/AGL/
14. AGL 8-K Filings - agilon health, inc. SEC 8-K - Stock Titan, https://www.stocktitan.net/sec-filings/AGL/8-k.html
15. agilon health Announces Reverse Stock Split (Form 8-K) - Public Technologies (PUBT), https://www.publicnow.com/view/812631F6BA2097B8072F2CEA07820382BA9EEF40
16. Corporate actions tracker - Robinhood, https://robinhood.com/us/en/support/articles/corporate-actions-tracker/
17. agilon health (AGL) Balance Sheet & Financial Health Metrics - Simply Wall St, https://simplywall.st/stocks/us/healthcare/nyse-agl/agilon-health/health
18. agilon health, inc. (AGL) Financials FY2025: Revenue $5.9B, Net Loss $391.3M | Income Statement & Balance Sheet - Stock Titan, https://www.stocktitan.net/financials/AGL/
19. UNITED STATES SECURITIES AND EXCHANGE COMMISSION FORM 10-Q agilon health, inc., https://d18rn0p25nwr6d.cloudfront.net/CIK-0001831097/cfd4f146-5094-46e5-91db-623adcee370f.pdf
20. agilon health (NYSE:AGL) - Stock Analysis - Simply Wall St, https://simplywall.st/stocks/us/healthcare/nyse-agl/agilon-health
21. Agilon Health, Inc. Stock Price: Quote, Forecast, Splits & News (AGL) - Perplexity, https://www.perplexity.ai/finance/AGL?comparing=AGL,VMD,TOI,BDSX,AHCO,LFMD
22. Why agilon health (AGL) Shares Are Falling Today - TradingView, https://www.tradingview.com/news/stockstory:c03919226094b:0-why-agilon-health-agl-shares-are-falling-today/
23. agilon JPM Investor Presentation, https://docs.publicnow.com/43EF872CB7817E70EC22B99479B8B7DA9567B0C6
24. Shareholders who lost money in shares of agilon health, inc. (NYSE: AGL) Should Contact Wolf Haldenstein Immediately - GlobeNewswire, https://www.globenewswire.com/news-release/2026/01/12/3217058/0/en/shareholders-who-lost-money-in-shares-of-agilon-health-inc-nyse-agl-should-contact-wolf-haldenstein-immediately.html
25. REMINDER: agilon health, inc. Investors With Significant Losses Must Act By March 2, 2026, https://www.businesswire.com/news/home/20260127681095/en/REMINDER-agilon-health-inc.-Investors-With-Significant-Losses-Must-Act-By-March-2-2026
26. April 17, 2026 - DEF 14A: Definitive proxy statements | Astrana Health, Inc. (ASTH), https://ir.astranahealth.com/sec-filings/all-sec-filings/content/0001104659-26-044536/tm261568d1_def14a.htm
27. Agilon Health Inc (AGL) - Stocks - Barchart.com, https://www.barchart.com/etfs-funds/quotes/AGL